

Carnegie Nordic Healthcare Seminar President & CEO Lars Rasmussen

Ostomy Care Urology & Continence Care Wound & Skin Care



Forward-looking statements

The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements are based on Coloplast's current expectations, estimates and assumptions and based on the information available to Coloplast at this time.

Heavy fluctuations in the exchange rates of important currencies, significant changes in the healthcare sector or major changes in the world economy may impact Coloplast's possibilities of achieving the long-term objectives set as well as for fulfilling expectations and may affect the company's financial outcomes.

Ostomy Care Urology & Continence Care Wound & Skin Care




Coloplast is a leading medtech company specialising in intimate healthcare needs...




50 years of innovation and growth:

- Global no. 1 in Ostomy Care
- Global no. 1 in Urology & Continence Care
- Global no. 4 in Advanced Wound & Skin Care
 Headquartered in Denmark
 Production in Denmark, Hungary, China, US
 and France



Ostomy Care Urology & Continence Care Wound & Skin Care





...with DKK 9.5bn in annual sales...

Ostomy Care Urology & Continence Care Wound & Skin Care



Stable intimate healthcare trends

Demographics

Emerging markets

Surgical and medical trends

Healthcare reforms

Growing elderly population increases customer base for Coloplast products

Expanding healthcare coverage for populations in emerging markets increases addressable market

Surgical and medical trends are towards earlier detection and cure, eventually reducing addressable market for Coloplast treatment products

Economic restraints push for reimbursement reforms, introduction of tenders, and lower treatment cost

Ostomy Care Urology & Continence Care Wound & Skin Care



Introducing Ostomy Care

Disease areas	Colorectal cancer (est. 55%) Bladder cancer (est. 10%) Inflammatory bowel disease (est. 35%)		
Customer groups	Nurses, mainly stoma care nurses People with a stoma Wholesalers/distribution Hospital purchasers and GPOs Surgeons		
Call points	Hospital & community nurses Hospital buyers Distributors Dealers Wholesalers Homecare companies		
Distribution of revenues	UrostomyIleostomyColostomy		

Ostomy Care Urology & Continence Care Wound & Skin Care

24 March 2011 Carnegie Nordic Healthcare Seminar Page 6

Key products





Assura® 1 and 2 piece 2nd generation launched 1996-2000





SenSura® 1 and 2 piece Launched in 2006-2008


Easiflex®, 2 piece flex Launched in 2003



The market for ostomy devices

- Global Market size estimated at DKK 10-11bn with 4-5% growth
- Market share: 35-40%
 - Europe 40-50%
 - Americas 0-10%
 - Rest of the world 10-20%
- Main competitors are ConvaTec and Hollister/Dansac





Market drivers

- Increasing incidence of colorectal cancer and inflammable bowel disease, particularly in developing countries
- Well developed usage patterns with strong key opinion leaders in Europe

Market limiters

- Reimbursement system reforms
- Usage patterns geared towards reuse of products outside Europe

Market trends

- National healthcare reforms aiming to reduce price and volume
- Increasing influence of financial decision makers within distribution and hospitals
- Improving treatment of stoma patients in developing economies

Ostomy Care Urology & Continence Care Wound & Skin Care



Introducing continence consumables

Disease areas	Spinal Cord Injured, SCI Spina Bifida, SB Multiple Sclerosis, MS Benign prostatic hyperplasia & prostatectomy patients Elderly and diabetics		
Customer groups	Continence or home care nurses People with incontinence problems Wholesalers/distribution Hospital purchasers and GPOs Surgeons		
Call points	Rehabilitation centers Urology wards Pediatric clinics Elderly homes Distributors, dealers & wholesalers		
Distribution of revenues	 Intermittent catheters Urine bags Male ext. catheters Other incl. bowel mgt. 		

Ostomy Care Urology & Continence Care Wound & Skin Care

24 March 2011 Carnegie Nordic Healthcare Seminar Page 8

Key products (management products)





SpeediCath® Compact intermittent catheter Launched in 03/04

SpeediCath® intermittent catheter Launched in 99/00



Conveen® Optima external catheter Launched in 05/06




Conveen® Security+ urine bag Launched 10+ years ago



The market for urinary incontinence management products

- Global Market size estimated at DKK 10-11bn with 4-6% growth
- Market share: 30-35%
 - Europe 40-50%
 - Americas 15-25%
 - Rest of the world 10-20%
- Main competitors include AstraTec and Bard



Market drivers

- Large, under-penetrated population for intermittent catheters
- Moving users away from old solutions (uncoated caths, diapers)
- Patient associations' influence is increasing

Market limiters

- Reimbursement system reforms (single price reimbursement on product categories)
- Commoditization and low-spec competitors entering

Market trends

- Purchasing decision centralized
- Diagnose Related Groups and tender business are increasing
- Health economic approach enables price premiums

Ostomy Care Urology & Continence Care Wound & Skin Care



Introducing Urology Care Treatment (surgical) of urological disorders

Disease areas	 Urinary incontinence Pelvic organ prolapse Erectile dysfunction Enlarged prostate Kidney and urinary stones 		
Customer groups	 Surgeons Purchasing departments and organizations End customers 		
Call points	 Urologists Uro-gynaecologists Gynaecologists Purchasing departments and organizations 		
Distribution of revenues	Men's healthWomen's healthDSU		

Ostomy Care Urology & Continence Care Wound & Skin Care

24 March 2011 Carnegie Nordic Healthcare Seminar Page 10

Key products (implants and surgical disposables)



Virtue® male sling Launched in 2009 Men's health - Surgical Urology



Aris® vaginal sling Launched in 2005 Women's health - Surgical Urology



Titan® OTR penile implant Launched in 2008 Men's health - Surgical Urology



JJ stents Launched in 1998 Disposable Surgical Urology




The market for urological disorders

- Global Market size estimated at DKK ~8bn with 8-10% growth
- Market share: 5-10%
 - Europe 15-25%
 - Americas 0-10%
 - Rest of the world 0-10%

• Main competitors include American Medical Systems, Ethicon, Medtronic and BSX





Market drivers

- Large, under-penetrated population
- Lack of gold standard treatment
- Ageing and obese population
- Minimally invasive surgeries

Market limiters

- Cost containment
- Increased competition
- Increased scrutiny on clinical proof
- Crowded IP landscape limits opportunities

Market trends

- Less invasive treatment methods
- Office-based treatments
- Cost containment
- Innovation key source of competitive advantage

Ostomy Care Urology & Continence Care Wound & Skin Care



Introducing Wound Care

Disease areas	Chronic woundsLeg ulcersDiabetic foot ulcersPressure ulcers		
Customer Groups & call points	 Hospitals Wound care committees Specialist nurses/doctors (Purchasers) Community Specialist nurses/doctors General practitioners District/general nurses Large nursing homes 		
Distribution of revenues (WSC)	■ Biatain® range ■ Comfeel® range		

Skin care

Other incl Compeed

Key products (Biatain® and Comfeel® range)





- Biatain® Silicone
- Silicone adhesive and foam dressing
- Launched in 2010

Biatain® Ag

- Antimicrobial foam dressing
- Launched in 2002



Biatain®

- High exudate mgt. foam dressing
- Launched in 1998



Comfeel® Plus Transparent • Transparent hydrocolloid dressing


• Launched in 1994

Ostomy Care Urology & Continence Care Wound & Skin Care



The market for advanced wound care where Coloplast competes

- Global Market size estimated at DKK 12-13bn with 5-7% growth
- Market share: 5-10%
 - Europe 10-15%
 - Americas 0-5%
 - Rest of the world 5-10%
- Main competitors include Convatec, Mölnlycke and S&N



Market drivers

- Ageing, diabetes, and obesity
- New and more expensive technologies (e.g. silver)
- Investments by industry in sales pressure driving conversion

Market limiters

- Healthcare reforms
- Increased competition
- Distribution taking an active role

Market trends

- Community based treatments
- Simple product offerings
- Cost containment


Ostomy Care Urology & Continence Care Wound & Skin Care



Improving financial performance driven by...

- Improving chronic care sales driven by high investments in professionalizing sales activities further
- •Transfer of production to low cost countries
- Efficiency gains throughout the organisation
- Lower capex-to-sales from higher capacity utilization and leaner factory footprint

.....Resulting in strong free cash flow generation and high return on invested capital.....



Ostomy Care Urology & Continence Care Wound & Skin Care



Guidance for 2010/11 confirms current trends, new longterm ambition confirms completion of turn-around

	Guidance 10/11	Guidance 10/11 (DKK)	Long-term ambition
Sales growth	6-8 % (organic)	8-10%	Market+
EBIT margin	23-25%(fixed)	23-25%	Deliver margins in line with the best performing medical device companies *)
CAPEX (DKKm)		300-400	4-5% of sales
Tax rate		~26%	-

*) The peer group includes the following listed companies: Medtronic Inc., Baxter International Inc., Covidien PLC, Stryker Corp., St. Jude Medical Inc., Boston Scientific Corp., Sonova Holding AG, Smith & Nephew PLC, CR Bard Inc., Getinge AB, WDH A/S, American Medical systems Inc.

Ostomy Care Urology & Continence Care Wound & Skin Care



Coloplast value proposition

Stable long-term growth potential

Growth and expansion potential

Strong customer driven innovation capabilities

Improving financial performance

Close relationships with nurses and endusers provide leading market positions within Ostomy & Continence Care

US and Emerging Markets hold high potential as well as the Surgical Urology and Wound Care businesses

Focus on providing more value for money for end users and public payers

Transfer of production to low cost countries improves production efficiencies. Lean administration

Ostomy Care Urology & Continence Care Wound & Skin Care



Our mission Making life easier for people with intimate healthcare needs

Our values Closeness... to better understand Passion... to make a difference Respect and responsibility... to guide us

Our vision Setting the global standard for listening and responding

Ostomy Care Urology & Continence Care Wound & Skin Care

